advertisement
14 Costing studies; pharmacoeconomics (12)
Showing records 1 to 12
Display all abstracts in classification 14 Costing studies; pharmacoeconomics
Search within classification 14 Costing studies; pharmacoeconomics24821 Direct and indirect effects of visual impairment on mortality risk in older persons
Karpa MJ; Mitchell P; Beath K; Rochtchina E; Cumming RG; Wang JJ; Blue Mountains Eye Study
Archives of Ophthalmology 2009; 127: 1347-1353
24655 A french economic model comparing cost-effectiveness of duotrav and xalacom in Glaucoma
Lafuma A; Laurendeau C; Berdeaux G
Value in Health 2009; 12: A455
24650 Interventional procedures in glaucoma: resources and costs in five european countries
Lafuma A; Verboven Y; Darba J; Brueggenjuergen B; Gylee E; Berto P
Value in Health 2009; 12: A460
24659 Cost effectiveness analysis of tafluprost compared with latanoprost on the treatment of primary open angle glaucoma in South Korea
Song HJ; Kang SH; Heo JH; Lee EK
Value in Health 2009; 12: A456-A457
24649 The application of discrete event simulation to quantitative risk benefit analysis
Maguire A; Douglas I; Blak BT
Value in Health 2009; 12: A453
24596 Healthcare charges in patients who transition from ocular hypertension to primary open-angle glaucoma based on ophthalmic coding data
Pasquale LR; Walt JG; Stern LS; Wiederkehr D; Malangone E; Dolgitser M
Advances in Therapy 2009; 1-12
24657 Costs of glaucoma in Denmark
Olsen J; Berdeaux G
Value in Health 2009; 12: A455
24865 The cost of care for people with impaired vision in Australia
Keeffe JE; Chou SL; Lamoureux EL
Archives of Ophthalmology 2009; 127: 1377-1381
24656 An economic analysis to evaluate anti-glaucoma pharmacotherapy
Bhowmik D; Sansgiry SS
Value in Health 2009; 12: A75
25005 Impact of the Activity-Based Financing (11(th) Version) on glaucoma surgery payment in hospital resources
Muselier A; Mathieu B; Aube H; Creuzot-Garcher C; Bron A
Journal Français d'Ophtalmologie 2009; 32: 701-706
24651 How and why automated medical databases should be used to create background occurrences for drug outcomes and safety studies: Glaucoma in thin (UK)
Maguire A; Blak BT
Value in Health 2009; 12: A489
24654 Micro-costing vs gross-costing in the estimation of costs for the pharmoeconomic evaluation of glaucoma in Korea
Kang SH; Lee EK
Value in Health 2009; 12: A234
